Chair’s Opening Remarks – Analytes in Liquid Biopsies as Oncologic Biomarkers for Early Detection and Drug Development

Time: 8:30 am
day: Day One


• How the field — Industry and academia — is progressing in finding disease earlier & surveying of assays currently available
• Issues of scientific validity: Standards, criteria for reimbursement, acceptable surrogate endpoints
• A survey of ongoing Multicancer Early Detection (MCED) with liquid biopsy—NGS and AI-derived signatures